Rosetta Resources Inc.
http://www.rosettaresources.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Rosetta Resources Inc.
Case Study: Cross-Strait Agreement Could Shorten IND Timeframe For Products Entering China (Part 2 of 2)
Global pharmaceutical firms can look no further than across the Taiwan Strait when working to get products approved and launched in China faster.
Australian biotechs fight over Progen
The Melbourne biotech firm Cytopia is challenging a merger between the Australian biotechs Progen Pharmaceuticals and Avexa, saying it can offer a better deal to Progen shareholders.
Progen and Avexa to merge
The Australian biotechnology companies Progen Pharmaceuticals and Avexaare set to merge. Progen has proposed to shareholders a A$20 million ($13.9 million) share buyback option at A$1.10 per share, to be completed before the merger. The combined company, which will be called Avexa Pharmaceuticals, will have around A$60 million in cash at the close of the transaction.
Taiwan's Medigen set to acquire Pacgen
Pacgen Biopharmaceuticals and the Taiwanese firm Medigen Biotechnology have signed a letter of intent to merge, in a deal to be completed next February. Current Medigen shareholders would own a majority of the as yet unnamed combined operation.
Company Information
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice